Abzena PLC Block Listing Update (9080A)

TIDMABZA

RNS Number : 9080A

Abzena PLC

03 January 2018

Abzena plc

Block Listing Update

Cambridge, UK, 3 January 2018 - Further to the announcement by Abzena plc (AIM: ABZA, 'Abzena' or the 'Group') on 3 July 2017, between 4 July 2017 and 3 January 2018, the Group announces that a total of 213,227 ordinary shares of GBP0.002 each in the share capital of the Group ('Ordinary Shares') have been issued pursuant to the Group's 2013 Share Incentive Plan and admitted to trading in accordance with the block listing applied for on 7 July 2015 (the 'Block Listing'). An update in accordance with Schedule 6 of the AIM Rules for Companies is set out below. Abzena holds no shares in treasury and hence the total number of current voting rights is 213,817,130.

BLOCK LISTING SIX MONTHLY RETURN

 
 Name of applicant:                                    Abzena plc 
----------------------------------------------------  ---------------------------------------------------------------- 
 Name of scheme:                                       Abzena plc 2013 Share Incentive Plan 
----------------------------------------------------  ---------------------------------------------------------------- 
 Period of return:           From:                     4 July 2017                 To:        3 January 2018 
--------------------------  ------------------------  --------------------------  ---------  ------------------------- 
 Balance of unallotted securities under scheme(s) 
  from previous return:                                757,476 
----------------------------------------------------  ---------------------------------------------------------------- 
 Plus: The amount by which the block scheme(s) has     Nil 
 been increased since the date of the last 
 return (if any increase has been applied for): 
----------------------------------------------------  ---------------------------------------------------------------- 
 Less: Number of securities issued/allotted under 
  scheme(s) during period (see LR3.5.7G):              213,227 
----------------------------------------------------  ---------------------------------------------------------------- 
 Equals: Balance under scheme(s) not yet 
  issued/allotted at end of period                     544,249 
----------------------------------------------------  ---------------------------------------------------------------- 
 Number and class of securities originally admitted    1,779,000 ordinary shares of GBP0.002 each, admitted on 13 July 
 and the date of admission                             2015 
----------------------------------------------------  ---------------------------------------------------------------- 
 Name of contact:                                      Julian Smith 
----------------------------------------------------  ---------------------------------------------------------------- 
 Telephone number of contact:                          [phone] 
----------------------------------------------------  ---------------------------------------------------------------- 
 
 

-Ends-

Enquiries:

 
 Abzena plc 
  John Burt, Chief Executive 
  Officer 
  Julian Smith, Chief Financial 
  Officer                          [phone] 
 
 Numis (Nominated Adviser and 
  Broker) 
  Clare Terlouw / James Black 
  / Paul Gillam                    [phone] 
 N+1 Singer (Joint Broker) 
  Aubrey Powell / Liz Yong         [phone] 
 Instinctif Partners               [phone] 
  Melanie-Toyne Sewell / Alex       [e-mail] 
  Shaw 
 

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

   --   Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; 
   --   Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

   --   Proprietary site-specific conjugation technologies and novel payloads for ADC development; and 
   --   GMP manufacturer of ADC linkers, payloads & combined linker-payloads. 

For more information, please see www.abzena.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BLRBJMPTMBBMBMP

(END) Dow Jones Newswires

January 03, 2018 13:12 ET (18:12 GMT)